Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
0.7497
-0.0604 (-7.46%)
Apr 29, 2026, 1:26 PM EDT - Market open
Dyadic International Revenue
In the year 2025, Dyadic International had annual revenue of $3.09M, down -11.59%. Dyadic International had revenue of $565.53K in the quarter ending December 31, 2025, a decrease of -30.81%.
Revenue (ttm)
$3.09M
Revenue Growth
-11.59%
P/S Ratio
9.86
Revenue / Employee
$515,058
Employees
6
Market Cap
27.32M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.09M | -405.04K | -11.59% |
| Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
| Dec 31, 2023 | 2.90M | -31.49K | -1.07% |
| Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
| Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
| Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
| Dec 31, 2019 | 1.68M | 385.63K | 29.77% |
| Dec 31, 2018 | 1.30M | 537.03K | 70.81% |
| Dec 31, 2017 | 758.42K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 40.58M |
| Evaxion | 7.53M |
| Pluri | 1.34M |
| IGC Pharma | 1.11M |
| Daré Bioscience | 1.03M |
| Outlook Therapeutics | 205.70K |
| Lisata Therapeutics | 170.00K |
| Senti Biosciences | 22.00K |
DYAI News
- 4 weeks ago - Dyadic International Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 6 weeks ago - Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices - GlobeNewsWire
- 6 weeks ago - Dyadic International Transcript: Life Sciences Virtual Investor Forum - Transcripts
- 6 weeks ago - Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026 - GlobeNewsWire
- 2 months ago - Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free) - GlobeNewsWire
- 2 months ago - Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone - GlobeNewsWire
- 2 months ago - Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin - GlobeNewsWire